Blueprint Medicines seeks a talented and highly motivated computational biologist to pursue research projects related to tumor immunology and contribute to the identification and development of the next generation of immune-based cancer therapies. The primary focus will be on generation and interpretation of high-throughput genomic and other molecular data that increase our understanding of: (1) Immune infiltration in the tumor microenvironment; (2) Mechanisms to avoid immune surveillance; and (3) Biomarkers which predict response to immunomodulatory drugs or therapies.
Applicants should have PhD in bioinformatics, biostatistics, computational biology or similar, with a strong publication Alternately, candidates may have a PhD in molecular biology combined with extensive experience in high-throughput data analysis.
Successful applicants must have in-depth understanding of current best practices in high- throughput molecular data analysis and broad experience with one or more platforms (e.g. next-generation sequencing, multiplexed qPCR, flow cytometry, proteomics).
Candidates should also have a strong background in using a high-level programming language, such as R, MATLAB, Python or Perl for complex data analysis.
Excellent communication, data presentation and visualization skills are also
A successful candidate will work with interdisciplinary teams, carry out data analysis and integration across various domains, and apply best-in-class algorithms (or develop new algorithms) that directly address the motivating biological and clinical questions. Regular publication of both scientific and methodological results is strongly encouraged. Finally, the successful candidate will be able to effectively present complex results in a clear and concise manner that is accessible to a diverse audience of quantitative, experimental, and clinical scientists. There is potential for a management/supervisory role for candidates who are more advanced in their careers.
Blueprint Medicines’ mission is to dramatically improve the lives of patients with genomically defined diseases. Our singular focus is to use our deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases to craft highly selective medicines aimed at eradicating these diseases. We are driven by the pursuit of new ideas, new innovations, and new ways of thinking. We believe we are at our best as a company when our employees are thriving and foster a culture that provides opportunities to grow and develop professionally, while also having fun.